Regression of Epileptogenesis by Inhibiting Tropomyosin Kinase B Signaling following a Seizure.

Abstract

OBJECTIVE:Temporal lobe epilepsy (TLE) is a devastating disease in which seizures persist in 35% of patients despite optimal use of antiseizure drugs. Clinical and preclinical evidence implicates seizures themselves as one factor promoting epilepsy progression. What is the molecular consequence of a seizure that promotes progression? Evidence from preclinical studies led us to hypothesize that activation of tropomyosin kinase B (TrkB)-phospholipase-C-gamma-1 (PLCγ1) signaling induced by a seizure promotes epileptogenesis. METHODS:To examine the effects of inhibiting TrkB signaling on epileptogenesis following an isolated seizure, we implemented a modified kindling model in which we induced a seizure through amygdala stimulation and then used either a chemical-genetic strategy or pharmacologic methods to disrupt signaling for 2 days following the seizure. The severity of a subsequent seizure was assessed by behavioral and electrographic measures. RESULTS:Transient inhibition of TrkB-PLCγ1 signaling initiated after an isolated seizure limited progression of epileptogenesis, evidenced by the reduced severity and duration of subsequent seizures. Unexpectedly, transient inhibition of TrkB-PLCγ1 signaling initiated following a seizure also reverted a subset of animals to an earlier state of epileptogenesis. Remarkably, inhibition of TrkB-PLCγ1 signaling in the absence of a recent seizure did not reduce severity of subsequent seizures. INTERPRETATION:These results suggest a novel strategy for limiting progression or potentially ameliorating severity of TLE whereby transient inhibition of TrkB-PLCγ1 signaling is initiated following a seizure. ANN NEUROL 2019;86:939-950.

Department

Description

Provenance

Subjects

Citation

Published Version (Please cite this version)

10.1002/ana.25602

Publication Info

Krishnamurthy, Kamesh, Yang Zhong Huang, Stephen C Harward, Keshov K Sharma, Dylan L Tamayo and James O McNamara (2019). Regression of Epileptogenesis by Inhibiting Tropomyosin Kinase B Signaling following a Seizure. Annals of neurology, 86(6). pp. 939–950. 10.1002/ana.25602 Retrieved from https://hdl.handle.net/10161/19539.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Huang

Yangzhong Huang

Assistant Research Professor of Neurobiology

The goal of my research is to elucidate the molecular and signaling mechanisms underlying epilepsy, a common and commonly devastating neurological disorder. There are two major objectives of my current work. I aim to understand the mechanisms by which brain-derived neurotrophic factor (BDNF) and its receptor tyrosine kinase TrkB transform the brain from normal to epileptic, a process termed epileptogenesis; and to develop peptide and small molecule inhibitors of TrkB signaling for prevention and disease modification of temporal lobe epilepsy.

Harward

Stephen Harward

Assistant Professor of Neurosurgery
McNamara

James O'Connell McNamara

Duke School of Medicine Distinguished Professor in Neuroscience

Our goal is to elucidate the cellular and molecular mechanisms underlying epileptogenesis, the process by which a normal brain becomes epileptic.  The epilepsies constitute a group of common, serious neurological disorders, among which temporal lobe epilepsy (TLE) is the most prevalent and devastating. Many patients with severe TLE experienced an episode of prolonged seizures (status epilepticus, SE) years prior to the onset of TLE. Because induction of SE alone is sufficient to induce TLE in diverse mammalian species, the occurrence of de novo SE is thought to contribute to development of TLE in humans.  Elucidating the molecular mechanisms by which an episode of SE induces lifelong TLE in an animal model will provide targets for preventive and/or disease modifying therapies.   Using a chemical-genetic method, we discovered a molecular mechanism required for induction of TLE by an episode of SE, namely, the excessive activation of the BDNF receptor tyrosine kinase, TrkB (Liu et al., 2013).  We subsequently discovered that phospholipase Cg1 is the dominant signaling effector by which excessive activation of TrkB promotes epilepsy (Gu et al., 2015).  We designed a novel peptide (pY816) that uncouples TrkB from phospholipase Cg1.  Treatment with pY816 following status epilepticus prevented TLE (Gu et al., 2015).  In addition to prevention, we have now shown that partial reversal of  epileptogenesis with pY816(Krishnamurthy et al., 2019), raising the possibility of ameliorating TLE after it has developed.   Collectively, these findings provide proof-of-concept evidence for a novel strategy targeting receptor tyrosine kinase signaling and identify a novel therapeutic for prevention and disease modification of TLE.   

 

There are two major objectives of our current work.    1.  We are developing peptide and small molecule inhibitors of TrkB signaling for advancement to the clinic. 2.  We seek to understand the cellular consequences of TrkB activation that transform the brain from normal to epileptic.  We have identified the sites within hippocampus at which SE-induced activation of TrkB occurs (Helgager et al 2013).  One is the spines of apical dendrites of CA1 pyramidal cells.  We are utilizing an in vitro model in which we mimic the enhanced synaptic release of glutamate during SE.  Using two photon uncaging microscopy, exquisitely localized high concentrations of glutamate are generated over a spine of an apical dendrite of a CA1 pyramidal cell in cultured hippocampus, resulting in long term potentiation. We have developed novel sensors to dynamically image activation of TrkB within a single spine. We have discovered that induction of long term potentiation requires activation of TrkB, mediated in part by uncaging induced release of BDNF from the same spine (Harward et al 2016).  This provides a valuable model with which to elucidate the mechanisms mediating activation of TrkB and the downstream signaling pathways by which its activation promotes long term potentiation (Hedrick et al 2016).

 

Helgager J, Liu G, McNamara JO.  The cellular and synaptic location of activated TrkB in mouse hippocampus during limbic epileptogenesis. J Comp Neurol. 521(3):499-521. 2013. (PMCID: PMC3527653)

Liu, G., Gu, B, He, X., Joshi, R.B., Wackerle, H.D., Rodriguiz, R.M., Wetsel, W.C., and McNamara, J.O. Transient Inhibition of TrkB Kinase after Status Epilepticus Prevents Development of Temporal Lobe Epilepsy. Neuron 79:31-38, 2013. (PMCID: PMC3744583).*

Gu, B., Huang,  Yang Zhong Huang, He, Xiao-Ping He, Joshi, R. B., Jang, Wonjo,  & McNamara, J.O.  A Peptide Uncoupling BDNF Receptor TrkB from Phospholipase Cγ1 Prevents Epilepsy Induced by Status Epilepticus.  Neuron 88(3):484-491, 2015.  PMID:26481038. PMCID: pending

Harward, S. C., Hedrick, N. G., Hall, C. E., Parra-bueno, P., Milner, T. A., Pan, E., … Yasuda, R., McNamara J.O. (2016). Autocrine BDNF-TrkB signalling within a single dendritic spine, 13–16. doi:10.1038/nature19766

Hedrick, N. G., Harward, S. C., Hall, C. E., Murakoshi, H., McNamara, J. O., & Yasuda, R. (2016). Rho GTPase complementation underlies BDNF-dependent homo- and heterosynaptic plasticity. Nature. doi:10.1038/nature19784

Krishnamurthy K, Huang YZ, Harward SC, Sharma KK, Tamayo DL, McNamara J.O.  Regression of Epileptogenesis by Inhibiting Tropomyosin B Signaling Following a Seizure. Annals of Neurology 86(6): 939-950, 2019.

 

Our publications can be found at: http://www.ncbi.nlm.nih.gov/sites/myncbi/1rMG926fr2ikx/bibliography/48320844/public/?sort=date&direction=ascending


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.